https://www.selleckchem.com/pr....oducts/semaxanib-su5
Visual analogue scale score decreased from 7.49 (2.03) to 3.08 (2.82) (P = 0.001). Currently, 71 patients are still on anakinra treatment. Treatment of 34 patients was discontinued (32%). Insufficient response and side effects were the most common reasons for treatment discontinuation. All of the side effects observed were reversible and the patients alleviated after treatment cessation. In four patients, leukopenia was observed. In patients who were refractory to colchicine, anti-IL-1 agent anakinra was shown to be effective a
Gefällt mir
Kommentar
Teilen
